Skip to Main Content

Paper Details

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
Leuk Lymphoma
3
2023
Author NameAffiliation
Daniel J DeAngeloDana-Farber Cancer Institute
Richard M StoneDana-Farber Cancer Institute
  • 1 - 2

Datasets

Release 1.2